Hietaranta-Luoma et al. (2015) evaluated the impact of genetic testing for the Apolipoprotein E (ApoE, a protein involved in Alzheimer's disease and cardiovascular disease and mapped to chromosome 19). The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.